PTN

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The Company's product development activities are focused on obesity, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity; ocular indications, including PL9643, an ophthalmic peptide solution for dry eye disease (DED), and ulcerative colitis, including PL8177, an oral peptide formulation. Its pipeline also includes PL7737 and PL9588. The Company's PL9588 is being developed as a topical treatment for glaucoma.

Wall Street analysts forecast PTN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PTN is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Palatin Technologies Inc revenue for the last quarter amounts to 8.85M USD, decreased % YoY.

Palatin Technologies Inc. EPS for the last quarter amounts to 4.26 USD, decreased -121.61 % YoY.

Palatin Technologies Inc (PTN) has 29 emplpoyees as of December 15 2025.

Today PTN has the market capitalization of 46.40M USD.